Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03297944 · ClinicalTrials.gov registry record · Phase 4
Sedative-Anxiolytic Effects on Simulated Driving Performance
A Phase 4 study of Psychomotor Impairment, sponsored by Marion Coe.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT03297944 is a Phase 4 study of Psychomotor Impairment that has completed, run by Marion Coe. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03297944, a Phase 4 study of Psychomotor Impairment, has completed, sponsored by Marion Coe.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the effect of anxiety drugs taken at night on the ability to drive a car the next day. Participants will receive alprazolam, placebo, or zolpidem at night before bed or in the morning before using a driving simulator to assess impairment.
Conditions Studied
Interventions
- DRUG Alprazolam 2mg (2ALP/PLC)
- DRUG Alprazolam 1mg (1ALP/PLC)
- DRUG Alprazolam 0.5mg (0.5ALP/PLC)
- DRUG Zolpidem 10mg (ZOL/PLC)
- DRUG Placebo (PLC/PLC)
Study Locations (1)
Kentucky
- Center on Drug and Alcohol Research - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-09-15 |
| Est. Completion | 2018-10-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03297944
The ClinicalTrials.gov registry entry for NCT03297944 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marion Coe, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psychomotor Impairment appearing as the primary indexed condition, and to 5 interventions - of which Alprazolam 2mg (2ALP/PLC) is the first listed.
NCT03297944 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT03297944 about?
NCT03297944 is a clinical study titled "Sedative-Anxiolytic Effects on Simulated Driving Performance". This study evaluates the effect of anxiety drugs taken at night on the ability to drive a car the next day. Participants will receive alprazolam, placebo, or zolpidem at night before bed or in the morning before using a driving simulator to assess impairment.
What is the current status of trial NCT03297944?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2017-09-15. Estimated completion is 2018-10-25.
What conditions does trial NCT03297944 study?
This clinical trial studies the following conditions: Psychomotor Impairment.
What interventions are being tested in trial NCT03297944?
The interventions under investigation include: Alprazolam 2mg (2ALP/PLC) (DRUG), Alprazolam 1mg (1ALP/PLC) (DRUG), Alprazolam 0.5mg (0.5ALP/PLC) (DRUG), Zolpidem 10mg (ZOL/PLC) (DRUG), Placebo (PLC/PLC) (DRUG).
Who is sponsoring clinical trial NCT03297944?
This trial is sponsored by Marion Coe, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03297944 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.